Aprea Therapeutics hits near 2-month high after Wedbush's 'outperform' rating

Aprea Therapeutics

08/07/2022 15:22

** Aprea Therapeutics' shares  APRE.O  jump as much as 32.5%
to a near-two-month high of $1.06 in early trade after brokerage
Wedbush initiates coverage on co with 'outperform' and $3 PT
    ** Stock now up 20%
    ** Brokerage optimistic after co's recent acquisition of
private biopharma company Atrin Pharmaceuticals as it refocuses
APRE's pipeline to target biomarkers called DNA damage response
(DDR) kinases  urn:newsml:reuters.com:*:nGNX5n8kQ4
    ** Adds it sees a large number of opportunities for
modulating DDR kinases in cancers
    ** Despite session gains, stock down by two-thirds in value
YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;))